Advertisement

Obesity Surgery

, Volume 19, Issue 6, pp 764–770 | Cite as

11β-Hydroxysteroid Dehydrogenase Type 1 is Overexpressed in Subcutaneous Adipose Tissue of Morbidly Obese Patients

  • Rodrigo Muñoz
  • Cristian Carvajal
  • Alex Escalona
  • Camilo Boza
  • Gustavo Pérez
  • Luis Ibáñez
  • Carlos FardellaEmail author
Research Article

Abstract

Background

11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme catalyzes interconversion of inactive cortisone to active cortisol. Its expression in adipose tissue has been associated with obesity and some of its metabolic disorders. Controversies regarding which fat depots [subcutaneous adipose tissue (SAT) or visceral adipose tissue (VAT)] have higher expression still remain. The aim of this work was to evaluate 11β-HSD1 expression in SAT and VAT of obese patients and evaluate its association to metabolic features of metabolic syndrome.

Methods

In 32 morbidly obese patients, paired samples of SAT and VAT were collected. All patients, 40.2 ± 12.3 years and 36.7 ± 3.8 body mass index (BMI), underwent sleeve gastrectomy or laparoscopic gastric bypass. Gene expression of 11β-HSD1 in adipose tissue samples were determined by real-time reverse transcriptase polymerase chain reaction. Spearman correlation test was used to evaluate relationships between 11β-HSD1 levels and clinical and biochemical parameters.

Results

11β-HSD1 mRNA levels were higher in SAT than in VAT, with median expression levels of 11.4 arbitrary units (AU) and 7.8 AU, respectively (p = 0.03). SAT 11β-HSD1 mRNA were correlated with VAT mRNA levels (r = −0.6, p = 0.018) and hip circumference (r = 0.66, p = 0.018). SAT 11β-HSD1 levels increase parallel according to BMI category. We did not find a correlation between SAT or VAT with fasting glucose (r = 0.15, p = NS), total cholesterol (r = 0.13, p = NS), triglycerides (r = 0.04, p = NS), and high-density lipoprotein (r = −0.16, p = NS). However, SAT expression in patients with features of MS was higher than those without features of MS.

Conclusions

Our results demonstrate that SATs express higher 11β-HSD1 mRNA levels than VAT. This finding highlights the importance of SAT in obesity and its possible role on metabolic disorders associated with obesity.

Keywords

Adipose tissue 11β-Hydroxysteroid dehydrogenase type 1 Morbid obesity Glucocorticoid Cortisol 

Notes

Acknowledgements

This work was supported by Chilean grant FONDECYT 1070876. Dr. Muñoz’s scholarship is funded by MECESUP and Faculty of Medicine, Pontificia Universidad Católica de Chile.

References

  1. 1.
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.CrossRefGoogle Scholar
  2. 2.
    National Cholesterol Education Program. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.CrossRefGoogle Scholar
  3. 3.
    Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16(5):442–3.CrossRefGoogle Scholar
  4. 4.
    Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782–7.CrossRefGoogle Scholar
  5. 5.
    Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses’ Health Study. Am J Epidemiol. 1997;145(7):614–9.CrossRefGoogle Scholar
  6. 6.
    Despres JP, Allard C, Tremblay A, et al. Evidence for a regional component of body fatness in the association with serum lipids in men and women. Metabolism. 1985;34(10):967–73.CrossRefGoogle Scholar
  7. 7.
    Despres JP, Moorjani S, Tremblay A, et al. Relation of high plasma triglyceride levels associated with obesity and regional adipose tissue distribution to plasma lipoprotein-lipid composition in premenopausal women. Clin Invest Med. 1989;12(6):374–80.PubMedGoogle Scholar
  8. 8.
    Gillum RF. The association of body fat distribution with hypertension, hypertensive heart disease, coronary heart disease, diabetes and cardiovascular risk factors in men and women aged 18–79 years. J Chronic Dis. 1987;40(5):421–8.CrossRefGoogle Scholar
  9. 9.
    Prineas RJ, Folsom AR, Kaye SA. Central adiposity and increased risk of coronary artery disease mortality in older women. Ann Epidemiol. 1993;3(1):35–41.CrossRefGoogle Scholar
  10. 10.
    Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280(21):1843–8.CrossRefGoogle Scholar
  11. 11.
    Thompson CJ, Ryu JE, Craven TE, et al. Central adipose distribution is related to coronary atherosclerosis. Arterioscler Thromb. 1991;11(2):327–33.CrossRefGoogle Scholar
  12. 12.
    Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–30.CrossRefGoogle Scholar
  13. 13.
    Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab. 2004;89(2):447–52.CrossRefGoogle Scholar
  14. 14.
    Bronnegard M, Arner P, Hellstrom L, et al. Glucocorticoid receptor messenger ribonucleic acid in different regions of human adipose tissue. Endocrinology. 1990;127(4):1689–96.CrossRefGoogle Scholar
  15. 15.
    Howlett TA, Rees LH, Besser GM. Cushing’s syndrome. Clin Endocrinol Metab. 1985;14(4):911–45.CrossRefGoogle Scholar
  16. 16.
    Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21(6):697–738.CrossRefGoogle Scholar
  17. 17.
    Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect “Cushing’s disease of the omentum”? Lancet. 1997;349(9060):1210–3.CrossRefGoogle Scholar
  18. 18.
    Krozowski Z, Li KX, Koyama K, et al. The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes. J Steroid Biochem Mol Biol. 1999;69(1–6):391–401.CrossRefGoogle Scholar
  19. 19.
    Masuzaki H, Tanaka T, Nakao K. Novel transgenic mouse model of the metabolic syndrome. Nippon Rinsho. 2004;62(6):1059–65.PubMedGoogle Scholar
  20. 20.
    Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes. 2004;53(4):931–8.CrossRefGoogle Scholar
  21. 21.
    Kotelevtsev Y, Holmes MC, Burchell A, et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A. 1997;94(26):14924–9.CrossRefGoogle Scholar
  22. 22.
    NIH. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991;115(12):956–61.CrossRefGoogle Scholar
  23. 23.
    Carrasco F, Klaassen J, Papapietro K, et al. A proposal of guidelines for surgical management of obesity. Rev Med Chil. 2005;133(6):699–706.CrossRefGoogle Scholar
  24. 24.
    Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefGoogle Scholar
  25. 25.
    Tchernof A, Belanger C, Morisset AS, et al. Regional differences in adipose tissue metabolism in women: minor effect of obesity and body fat distribution. Diabetes. 2006;55(5):1353–60.CrossRefGoogle Scholar
  26. 26.
    Reynisdottir S, Dauzats M, Thorne A, Langin D. Comparison of hormone-sensitive lipase activity in visceral and subcutaneous human adipose tissue. J Clin Endocrinol Metab. 1997;82(12):4162–6.PubMedGoogle Scholar
  27. 27.
    Rebuffe-Scrive M, Andersson B, Olbe L, Bjorntorp P. Metabolism of adipose tissue in intraabdominal depots of nonobese men and women. Metabolism. 1989;38(5):453–8.CrossRefGoogle Scholar
  28. 28.
    Van Harmelen V, Lonnqvist F, Thorne A, et al. Noradrenaline-induced lipolysis in isolated mesenteric, omental and subcutaneous adipocytes from obese subjects. Int J Obes Relat Metab Disord. 1997;21(11):972–9.CrossRefGoogle Scholar
  29. 29.
    Mauriege P, Marette A, Atgie C, et al. Regional variation in adipose tissue metabolism of severely obese premenopausal women. J Lipid Res. 1995;36(4):672–84.PubMedGoogle Scholar
  30. 30.
    Fried SK, Kral JG. Sex differences in regional distribution of fat cell size and lipoprotein lipase activity in morbidly obese patients. Int J Obes. 1987;11(2):129–40.PubMedGoogle Scholar
  31. 31.
    Michailidou Z, Jensen MD, Dumesic DA, et al. Omental 11beta-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. Obesity (Silver Spring). 2007;15(5):1155–63.CrossRefGoogle Scholar
  32. 32.
    Wake DJ, Rask E, Livingstone DE, et al. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab. 2003;88(8):3983–8.CrossRefGoogle Scholar
  33. 33.
    Desbriere R, Vuaroqueaux V, Achard V, et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring). 2006;14(5):794–8.CrossRefGoogle Scholar
  34. 34.
    Paulsen SK, Pedersen SB, Fisker S, Richelsen B. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring). 2007;15(8):1954–60.CrossRefGoogle Scholar
  35. 35.
    Tomlinson JW, Sinha B, Bujalska I, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab. 2002;87(12):5630–5.CrossRefGoogle Scholar
  36. 36.
    Goedecke JH, Wake DJ, Levitt NS, et al. Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin Endocrinol (Oxf). 2006;65(1):81–7.CrossRefGoogle Scholar
  37. 37.
    Bujalska IJ, Quinkler M, Tomlinson JW, et al. Expression profiling of 11beta-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes. J Mol Endocrinol. 2006;37(2):327–40.CrossRefGoogle Scholar
  38. 38.
    Alberti L, Girola A, Gilardini L, et al. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects. Int J Obes (Lond). 2007;31(12):1826–31.CrossRefGoogle Scholar
  39. 39.
    Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. Endocrinology. 2001;142(4):1371–6.CrossRefGoogle Scholar
  40. 40.
    Berger J, Tanen M, Elbrecht A, et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem. 2001;276(16):12629–35.CrossRefGoogle Scholar
  41. 41.
    Tomlinson JW, Moore J, Cooper MS, et al. Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology. 2001;142(5):1982–9.CrossRefGoogle Scholar
  42. 42.
    Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41(10):1241–8.CrossRefGoogle Scholar
  43. 43.
    Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care. 2002;5(5):551–9.CrossRefGoogle Scholar
  44. 44.
    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91.CrossRefGoogle Scholar
  45. 45.
    Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994;43(11):1271–8.CrossRefGoogle Scholar
  46. 46.
    Boivin A, Brochu G, Marceau S, et al. Regional differences in adipose tissue metabolism in obese men. Metabolism. 2007;56(4):533–40.CrossRefGoogle Scholar
  47. 47.
    Mattsson C, Olsson T. Estrogens and glucocorticoid hormones in adipose tissue metabolism. Curr Med Chem. 2007;14(27):2918–24.CrossRefGoogle Scholar
  48. 48.
    Turpeinen U, Markkanen H, Sane T, Hamalainen E. Determination of free tetrahydrocortisol and tetrahydrocortisone ratio in urine by liquid chromatography-tandem mass spectrometry. Scand J Clin Lab Invest. 2006;66(2):147–59.CrossRefGoogle Scholar
  49. 49.
    Mariniello B, Ronconi V, Rilli S, et al. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing’s syndrome. Eur J Endocrinol. 2006;155(3):435–41.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Rodrigo Muñoz
    • 2
    • 3
  • Cristian Carvajal
    • 1
  • Alex Escalona
    • 2
  • Camilo Boza
    • 2
  • Gustavo Pérez
    • 2
  • Luis Ibáñez
    • 2
  • Carlos Fardella
    • 1
    Email author
  1. 1.Department of Endocrinology, Faculty of MedicinePontificia Universidad Católica de ChileSantiagoChile
  2. 2.Department of Digestive Surgery, Faculty of MedicinePontificia Universidad Católica de ChileSantiagoChile
  3. 3.Medical Sciences PhD Program, Faculty of MedicinePontificia Universidad Católica de ChileSantiagoChile

Personalised recommendations